Key result
Antiplatelet therapy, oral anticoagulants, and their combination were associated with a greater risk of major bleeding compared to no treatment.
Why the study?
Does antiplatelet and/or oral anticoagulant therapy increase the risk of major bleeding in adult chronic hemodialysis patients?
Cohort (n=502)
Yes
Does antiplatelet and/or oral anticoagulant therapy increase the risk of major bleeding in adult chronic hemodialysis patients?
In chronic hemodialysis patients, the use of antiplatelet agents, oral anticoagulants, or their combination is associated with a significantly increased risk of major bleeding compared to no antithrombotic treatment.
Answers are grounded in this paper and cite their sources.
Antithrombotic therapy was associated with higher major bleeding risk in hemodialysis; leaves open optimal regimens pending randomized trials.
PURPOSE: Results of previous studies assessing the risk of bleeding associated with prescription of antiplatelet (AP) and/or oral anticoagulant (AC) therapy to hemodialysis patients are conflicting. Our purpose was to describe practices for prescription of AP and AC in hemodialysis patients in the Lorraine region, and to assess their effect on the risk of major bleeding events. METHODS: All adults with chronic kidney disease who began a first renal replacement therapy by hemodialysis in 2009 or 2010 in one of the 12 dialysis centers in Lorraine were included in the Thrombosis and Hemorrhage in HemoDialysis patients (T2HD) study and followed up until 30 June 2013. The association of each treatment (AP, AC, AP + AC) with the risk of major bleeding was estimated by three Cox proportional hazard models with an inverse probability of treatment weighting on a propensity score, considering the untreated patients as the reference. RESULTS: Among 502 patients included, 227 (45.2%) received an AP, 68 (13.5%) an AC, 81 (16.1%) a combination AP + AC, and 126 (25.1%) were untreated. As compared with untreated patients, those given AP (HR 5.52, 95% CI [3.11-9.80]), AC (HR: 4.15, 95% CI: [3.46-4.99]), and AP + AC (HR: 5.59, 95% CI [2.62-11.91]) were at greater risk of major bleeding events. CONCLUSIONS: The risk of major bleeding is higher in patients receiving an oral AC compared with untreated patients and those receiving an AP agent. A combination of the two drugs does not seem to increase the risk.
No takes yet. Share an insight, caveat, or question.
Collette et al. (2016) conducted a cohort in Chronic kidney disease on hemodialysis (n=502). Antiplatelet and/or oral anticoagulant therapy vs. Untreated patients was evaluated on Major bleeding events (HR 5.52, 95% CI 3.11-9.80). Antiplatelet therapy, oral anticoagulants, and their combination were associated with a greater risk of major bleeding compared to no treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: